Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells

Anti-Cancer Drugs

Volumn 17, Issue 3, 2006, Pages 269-278

  Aoki, Shunji ^a   Cho, Seok Hwan ^a   Ono, Mayumi ^b   Kuwano, Takashi ^b   Nakao, Shintaro ^b   Kuwano, Michihiko ^c   Nakagawa, Shinsaku ^a   Gao, Jian Qing ^a   Mayumi, Tadanori ^a   Shibuya, Masabumi ^d   Kobayashi, Motomasa ^a  

^a OSAKA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KURUME UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Anti angiogenesis; Anti tumor activity; Apoptosis; Bastadin 6

Indexed keywords

ANTINEOPLASTIC AGENT; BASTADIN 6; BROMINE; CASPASE 3; CASPASE 7; COMPLEMENTARY DNA; DOXORUBICIN; ETOPOSIDE; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RECOMBINANT VASCULOTROPIN; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CELL MIGRATION; CONTROLLED STUDY; CORNEA; ENDOTHELIUM CELL; FEMALE; FIBROBLAST; GROWTH INHIBITION; HUMAN; HUMAN CELL; MARINE ENVIRONMENT; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SOLID TUMOR; SPONGE (PORIFERA); TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL GROWTH PROCESSES; CORNEA; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; HALOGENATED DIPHENYL ETHERS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; NIH 3T3 CELLS; PORIFERA; RATS; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33646085774     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200603000-00005     Document Type: Article

References (38)

1. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267:10931-10934.
2. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-4599.
3. Veronese ML, O'Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 2004; 40:1292-1301.
4. Beliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, et al. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin Cancer Res 2002; 8:1242-1250.
5. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62:4645-4655.
6. Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenesis and antitumor effects. Cancer Res 2003; 63:8890-8898.
7. Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, et al. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 2003; 63:7301-7309.
8. Dudley A, Gilbert RE, Thomas D, Cox A, Price JT, Best J, et al. STI-571 inhibits in vitro angiogenesis. Biochem Biophys Res Commun 2003; 310:135-142.
9. Naglich JG, Jure-Kunkel M, Gupta E, Fargnoli J, Henderson AJ, Lewin AC, et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 2001; 61:8480-8485.
10. v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 2002; 98:690-697.
11. Dhanabal M, Ramchandran R, Waterman MJF, Lu H, Knebelmann B, Segal M, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999; 274:11721-11726.
12. 4.5-mediated apoptosis of vascular endothelial cells. Cancer Res 2003; 63:4275-4280.
13. 0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci USA 2001; 98:6656-6661.
14. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6:41-48.
15. Guo N, Krutzsch HC, Inman JK, Robert DD. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 1997; 57:1735-1742.
16. Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res 2002; 62:3711-3715.
17. Aoki S, Naka Y, Itoh T, Furukawa T, Rachmat R, Akiyama S, et al. Lembehsterols A and B, novel sulfated sterols inhibiting thymidine phosphorylase, from the marine sponge Petrosia strongylata. Chem Pharm Bull 2002; 49:827-830.
18. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K, et al. Angiogenic factor. Nature 1992; 356:668.
19. Kazlaukas R, Lidgard RO, Murphy PT, Wells RJ, Blount JF. Brominated tyrosine-derived metabolites from the sponge lanthella basta. Aust J Chem 1981; 34:765-786.
20. Takahashi T, Shibuya M. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH 3T3 fibroblasts. Oncogene 1997; 14:2079-2089.
21. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995; 10:135-147.
22. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62:2554-2560.
23. Fong TAT, Shawver LK, Sun L, Tang C, App H, Powell TJ, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59:99-106.
24. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 2004; 10:88-95.
25. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 60:4152-4160.
26. Willett CG, Boucher Y, Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-147.
27. Gyorffy S, Palmer K, Podor TJ, Hitt M, Gauldie J. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy. J Immunol 2001; 166:6212-6217.
28. Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994; 69:212-216.
29. WAF1/CIP1. Proc Natl Acad Sci USA 2000; 97:6427-6432.
30. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000; 275:1209-1215.
31. Panka DJ, Mier JW. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem 2003; 278:37632-37636.
32. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matusuzawa Y, Zhivotovsky B, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004; 101:2476-2481.
33. Griffith EC, Su Z, Niwayama S, Ramsay C, Chang Y, Liu J. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc Natl Acad Sci USA 1998; 95:15183-15188.
34. Asami Y, Kakeya H, Onose R, Chang Y, Toi M, Osada H. RK-805, an endothelial-cell-growth inhibitor produced by Neosartorya sp., and a docking model with methionine aminopeptidase-2. Tetrahedron 2004; 60:7085-7091.
35. Mack MM, Molinski TF, Buck ED, Pessah IN. Novel modulators of skeletal muscle FKBP12/calcium channel complex from lanthella basta. J Biol Chem 1994; 269:23236-23249.
36. 3H1 cells. Am J Physiol 1997; 41:C601-C614.
37. 2+ channel in an FKBP12-dependent manner. J Biol Chem 1999; 46:32603-32612.
38. Kohler R, Brakemeier S, Kuhn M, Degenhardt C, Buhr H, Pries A, et al. Expression of ryanodine receptor type 3 and TRP channels in endothelial cells: comparison of in situ and cultured human endothelial cells. Cardiovasc Res 2001; 51:160-168.